



## **Ventripoint adds Experienced Cardiac Sonographer to the Installation and Training Team**

**Toronto, Ontario, May 23, 2018** – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce the appointment of Jim Graba, BSc, RDCS, FASE as Application Specialist and Chief Trainer. Jim will take the clinical lead in the deployment and training of customers. In addition, he will provide product strategy and direction for the development team.

“Jim’s appointment is very timely as he adds clinical depth to our deployment team with a focus on broadening the use of the VMS+ in collaboration with our existing and future users,” commented Desmond Hirson, President of Ventripoint.

Jim previously held positions in the healthcare field, including Chief Cardiac Sonographer at the Toronto General Hospital and Manager of Echocardiography at the University Health Network. His decades of experience make him keenly aware of workflows and methodologies within the clinical and research Echo environments. He is well known as an innovator, with multiple medical publications, and as mentor in the Echo community. His commercial experience with the development and deployment of other ultrasound technologies with VisualSonics, as Product and Applications Specialist, makes him exceptionally well qualified to assist in evolving the VMS+ to have even broader applications. Jim is also a certified Health Informatics professional and will be key in installing Ventripoint products into the sophisticated digital environment of hospitals and institutions throughout the world.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: [gadams@ventripoint.com](mailto:gadams@ventripoint.com)

### **Forward Looking Statements:**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the

Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**